| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910909 | Lung Cancer | 2014 | 34 Pages |
Abstract
Dual inhibition of EGFR and AKT may be a useful up-front strategy for patients with EGFR-mutant and -wild-type non-small cell lung cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Puglisi, P. Thavasu, A. Stewart, J.S. de Bono, M.E.R. O'Brien, S. Popat, J. Bhosle, U. Banerji,